Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Do vasodilators help in chronic heart failure?].

J Slany

    Wiener Klinische Wochenschrift
    |March 6, 1987
    PubMed
    Summary
    This summary is machine-generated.

    Vasodilator drugs, particularly converting enzyme inhibitors, offer long-term improvement for advanced heart failure patients. These agents enhance hemodynamics, relieve symptoms, and may reduce mortality, unlike some other vasodilators.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [J curve: when lowering blood pressure becomes a hazard?].

    Der Internist·2013
    Same author

    [Hypertension and nutrition. Position paper of the Austrian Nutrition Society].

    Herz·2012
    Same author

    [Arterial stiffness and pulse wave analysis].

    Deutsche medizinische Wochenschrift (1946)·2010
    Same author

    [Kawasaki disease and its ocular manifestations].

    Casopis lekaru ceskych·2008
    Same author

    [A rare complication of acute lymphoblastic leukaemia in young patients].

    Casopis lekaru ceskych·2007
    Same author

    Is left ventricular hypertrabeculation/ noncompaction a cardiac manifestation of Fabry's disease?

    Zeitschrift fur Kardiologie·2003
    Same journal

    [Vaccination of immunocompromised individuals: Expert opinion - update 2026].

    Wiener klinische Wochenschrift·2026
    Same journal

    Systematic review of clinical evidence for Kneipp medicine.

    Wiener klinische Wochenschrift·2026
    Same journal

    Pelvic resections in primary sarcomas : Surgical outcomes and survival analysis of 75 patients.

    Wiener klinische Wochenschrift·2026
    Same journal

    Jungmediziner*innen am Start: 11. Workshop für den medizinischen Nachwuchs.

    Wiener klinische Wochenschrift·2026
    Same journal

    Stellungnahme der ÖGP zur geplanten Gesetzesnovelle zum Nichtraucherschutzgesetz.

    Wiener klinische Wochenschrift·2026
    Same journal

    MUW researcher of the month: Dr. Moritz Schaefer.

    Wiener klinische Wochenschrift·2026
    See all related articles

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • Chronic congestive heart failure (CHF) management often involves multiple drug classes.
    • The role of vasodilators in advanced CHF requires ongoing evaluation.

    Purpose of the Study:

    • To review the efficacy of various vasodilator drugs in treating chronic congestive heart failure.
    • To assess long-term outcomes based on published randomized, double-blind, placebo-controlled trials.

    Main Methods:

    • Systematic review of randomized, double-blind, placebo-controlled trials.
    • Analysis of clinical data on vasodilator drug efficacy in CHF patients.

    Main Results:

    • Venous or combined venous and arteriolar dilation aids long-term improvement in advanced CHF.

    Related Experiment Videos

  • Vasodilators with isolated afterload reduction show limited value.
  • Nitrates and alpha-blockers offer modest improvement, often limited by tolerance.
  • Converting enzyme inhibitors demonstrate significant benefits, including improved hemodynamics, symptom relief, and potential mortality reduction with minimal tolerance.

    • Conclusions:

    • Converting enzyme inhibitors are highly effective for advanced CHF, improving hemodynamics and reducing mortality.
    • Combined therapy with cardiac glycosides and diuretics alongside specific vasodilators can improve outcomes.
    • Vasodilators with isolated afterload reduction are less beneficial for long-term CHF management.